◼ Archived
Business
Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Novartis's pelacarsen fails to reduce cardiovascular events in the Lp(a)HORIZON trial, casting doubt on lipoprotein(a) as a drug target and AI-driven drug discovery.